Industry Genomics Network Alliance (InGeNA)
Pictured: Chair of the InGeNA David Bunker launching the Alliance at the Digital Health Institute Summit in Brisbane, November 2020.
The Industry Genomics Network Alliance (InGeNA) addresses the need for a central group to represent Industry across the genomics value chain (diagnostics, bioinformatics, cloud, data, pharma and technology), and provide a combined and compelling voice.
InGeNA provides an independent, trusted, credible industry perspective to inform and develop genomics policy and to work collaboratively with research, government and service providers across the genomics and health sectors.
InGeNA will work collaboratively with other bodies and will focus on enabling access and improved outcomes for Australians as well as the economic strength and capability of Australia to be a global leader in genomics and deliver precision health at a population level.
Outcomes: The project now has 18 industry members and held a national genomics conference in June 2021, as well a monthly webinar series. A series of report are being developed focusing on data, the value of genomics, workforce, access and equity
|Consortium Lead||The Australasian Institute of Digital Health |
|Consortium Members||23 strands, AbbVie, Amgen, Amicus Therapeutics, Applied Precision Medicine, Bristol Myers Squibb, Illumina, Janssen, Qiagen, Roche, Sanofi, Thermo Fisher, Trakgene|
|Project Duration||October 2020 - February 2022 (Finished)|
|Project Contact||Carla Carroll, Project manager at The Australasian Institute of Digital Health|
Visit The Australasian Institute of Digital Health for more information.
Visit the InGeNA website to learn more | Twitter: @TheInstituteDH
Check out the announcement here.